Evidence map›Paper›PMID 32102899›Full record

ReviewClinical microbiology reviews2020

Epidemiology of β-Lactamase-Producing Pathogens.

Karen Bush, Patricia A Bradford

Open access · bronzeAbstract readReview
In one paragraph

Review in Clinical microbiology reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 531 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
531citing papers in PubMed, 3 pooled it
31.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

531 citing papers in PubMed, 3 syntheses or guidelines pooled it, 866 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Drug-likeness prioritised selection identifies anti-Journal of enzyme inhibition and medicinal chemistry · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. UropathogenicAntibiotics (Basel, Switzerland) · 2026
    Review
  13. Article
  14. Comparison of oral third- versus first-/ second-generation cephalosporins for acute uncomplicated cystitis: a nationwide retrospective cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Genomic Characterization, Antimicrobial Resistance Profiles, andAnimals : an open access journal from MDPI · 2026
    Article

471 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Karen Bush *Department of Biology, Indiana University, Bloomington, Indiana, USA karbush@indiana.edu.ORCID 0000-0002-7843-2474
Patricia A Bradford *Antimicrobial Development Specialists, LLC, Nyack, New York, USA.ORCID 0000-0002-1285-2978
Indiana University Bloomington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

β-Lactam antibiotics have been widely used as therapeutic agents for the past 70 years, resulting in emergence of an abundance of β-lactam-inactivating β-lactamases. Although penicillinases in

Indexed as

Drug Resistance, Multiple, BacterialAnimalsAnti-Bacterial AgentsBacteriaBacterial InfectionsBacterial Proteinsbeta-Lactamasesbeta-LactamsClinical Laboratory TechniquesHumansPlasmidsAnti-Bacterial AgentsBacterial Proteinsbeta-Lactamasesbeta-Lactamscarbapenemasebeta-lactamasecarbapenemaseepidemiologyESBLresistance

Identifiers

PMID32102899
PMCPMC7048014
OpenAlexW3007020664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.